When GLP-1 receptor agonists and those new multi-agonist weight-loss drugs started blowing up the headlines, the initial knee-jerk reaction across the orthopedic world was pretty predictable: “If everyone starts dropping 40 pounds, will joint wear slow down enough to hit our total joint volumes?”
It sounded logical on paper. Less body weight means less mechanical load pounding on knees and hips every day. But if you talk to the surgeons on the ground in the ASCs or look at the actual patient funnels filling up orthopedic clinics across the country, a completely different reality is playing out.
GLP-1s aren't killing surgical demand in orthopedics. They are unlocking it.
We are watching a massive structural shift in musculoskeletal care right now. Metabolic optimization is moving from an insurmountable wall into an intentional, structured pre-habilitation strategy.
The High-BMI Wall Is Finally Falling
For as long as I’ve been in this industry, one of the most frustrating consults in orthopedics has been the patient sitting on the exam table with end-stage, bone-on-bone osteoarthritis whose BMI is well over 40.
Surgeons know the patient is in agony. But they also know the numbers: hi...
